Hemab Therapeutics Holdings, Inc. Common Stock (COAG) Stock Forecast & Price Target

Hemab Therapeutics Holdings, Inc. Common Stock (COAG) has an ST Score of 73.5 (B+), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.

Analysts rate COAG a Buy, with a price target of $51.40 (+50.4% vs the current price). Our ST Score grades it B+ (73.5/100). The ST Score is a data-driven signal, not a recommendation.

Valuation A, Profitability A-, Financial Strength A+, Momentum B-, Growth B-, Forecast B.

Hemab Therapeutics Holdings, Inc. Common Stock (COAG) earns a valuation grade of A, measured against Biotechnology peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.

Hemab Therapeutics Holdings, Inc. Common Stock (COAG) earns a growth grade of B-, measured against Biotechnology peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.

Hemab Therapeutics Holdings, Inc. Common Stock (COAG) earns a profitability grade of A-, measured against Biotechnology peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.

Hemab Therapeutics Holdings, Inc. Common Stock (COAG) earns a financial strength grade of A+, measured against Biotechnology peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.

The average analyst price target for Hemab Therapeutics Holdings, Inc. Common Stock (COAG) is $51.40 from 3 analysts, which is +50.4% versus the recent price of $34.17.